ALK and non-small cell lung carcinoma: Thirty-eight advanced NSCLC patients who had progressed on one line of platinum-based chemotherapy or first-line of targeted therapy of EGFR inhibitor or ALK inhibitor were enrolled in a phase II trial of bemcentinib in combination with pembrolizumab.